You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,399,641


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,399,641
Title:Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 (TSSC6)
Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 and methods of use.
Inventor(s): Ryan; James (Augusta, GA)
Assignee: Ryogen LLC (Suffern, NY)
Application Number:13/244,463
Patent Claims:1. An isolated polynucleotide selected from the group consisting of: (a) an isolated polynucleotide consisting of a nucleic acid sequence which is at least 99% identical to the polynucleotide shown in SEQ ID NO:9; (b) a polynucleotide fragment of (a) comprising at least nucleotides 5011-20067 of SEQ ID NO:9, wherein (a)-(b) encode a polypeptide which is at least 99% identical to SEQ ID NO:3 and has human tumor suppressing subtransferable candidate 6 (TSSC6) activity or (c): a reverse strand of the polynucleotides of (a) or (b).

2. A nucleic acid construct comprising the polynucleotide of claim 1.

3. An expression vector comprising the polynucleotide of claim 1.

4. A recombinant host cell comprising the polynucleotide of claim 1.

5. A method for obtaining human tumor suppressing subtransferable candidate 6 (TSSC6) comprising: (a) culturing the recombinant host cell of claim 4 under conditions that provide for obtaining human tumor suppressing subtransferable candidate 6 (TSSC6) and (b) recovering said human tumor suppressing subtransferable candidate 6 (TSSC6).

6. An isolated polynucleotide at least 50 nucleotides in length identical to a region of SEQ ID NO: 9, said region selected from the group consisting of a Sr-noncoding region, an intron, a 3'-non-coding region and a contiguous coding and non-coding nucleic acid region of SEQ ID NO:9 or reverse strand of said polynucleotide.

7. The isolated polynucleotide of claim 6, wherein the 5'-noncoding region consists of nucleotides 20067-30196 of SEQ ID NO:9, the intron is selected from the group consisting of nucleotides 5101-6248, 6348-10878, 10954-15796, 15899-16627, 16715-18371, 18456-18718, 18812-19488, 19665-20004 of SEQ ID NO:9 and a 3'-noncoding region consists of nucleotides 1-5010 of SEQ ID NO:9.

8. A composition comprising the polynucleotide of claim 1 and a carrier or diluent.

9. A composition comprising the polynucleotide of claim 6 and a carrier or diluent.

10. A kit comprising the polynucleotide of claim 1.

11. A kit comprising the polynucleotide of claim 6.

12. A method for detecting the presence or absence of a nucleic acid sequence of SEQ ID NO: 9 or its complementary sequence in a sample, said method comprising contacting the sample with the polynucleotide of claim 6.

13. A method of detecting the presence or absence of a variant of human tumor supressing subtransferable candidate 6 (TSSC6) in a sample using the polynucleotide of claim 1.

14. A method for obtaining the polynucleotide of claim 1 comprising (a) isolating genomic polynucleotide from a subject; (b) providing primers, probes and optionally polymerase, wherein said primers or probes are at least 50 nucleotides in length identical to a region of SEQ ID NO: 9, said region selected from the consisting of a noncoding region, an intron, a 3'-non-coding region and a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:9 or reverse strand of said regions and (c) incubating (a) and (b) under conditions promoting the isolation of said polynucleotide.

15. A method for obtaining the polynucleotide of claim 6 comprising (a) isolating genomic polynucleotide from a subject; (b) providing primers, probes and optionally polymerase, wherein said primers or probes are at least 50 nucleotides in length identical to a region of SEQ ID NO: 9, said region selected from the group consisting of a 5'-noncoding region, an intron a 3'-non-coding region and a contiguous coding and non-coding nucleic acid sequence region of SEQ ID NO:9 or reverse strand of said regions and (c) incubating (a) and (b) under conditions promoting the isolation of said polynucleotide.

16. The polynucleotide according to claim 1, wherein said polynucleotide is DNA or RNA.

17. An isolated polynucleotide consisting of a 5'-noncoding region, an intron, a 3'-non-coding region or a contiguous coding and non-coding nucleic acid region of SEQ ID NO:9 or reverse strand of said polynucleotide, wherein the 5'-noncoding region consists of nucleotides 20067-30196 of SEQ ID NO:9, the intron is selected from the group consisting of nucleotides 5101-6248, 6348-10878, 10954-15796, 15899-16627, 16715-18371, 18456-18718, 18812-19488, 19665-20004 of SEQ ID NO:9 and a 3'-noncoding region consists of nucleotides 1-5010 of SEQ ID NO:9.

18. An isolated polynucleotide fragment of the isolated polynucleotide of claim 17, wherein said fragment is at least 500 nucleotides in length.

19. The method according to claim 14, wherein said polynucleotide is DNA or RNA.

20. The method according to claim 15, wherein said polynucleotide is DNA or RNA.

21. The polynucleotide of claim 6, wherein said polynucleotide is DNA or RNA.

22. The polynucleotide of claim 17, wherein said polynucleotide is DNA or RNA.

23. A kit comprising the polynucleotide of claim 17.

Details for Patent 8,399,641

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2020-10-31
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2020-10-31
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2020-10-31
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.